





Rituximab Order Form

Patient Nan	ne:			DOB:		
			Address:			
Sex:	Height:	Weight:		Allergies:		
DIAGNOSIS	:					
	matoid Arthritis ICD-10:		☐ Pe	emphigus Vulgaris ICD-10:		
☐ Gran	ulomatosis w/Polyangitis IC	CD-10:		icroscopic Polyangitis ICD-10:		
	r:					
ORDER FOR	RITUXIMAB:					
		biosimilar as require	d by patient's	insurance determination	າ x 1 vear	
	d product to be determ	•			7	
	<u>ubstitute</u> : Continue to	-				
		tuxience 🗆 Truxir	_			
				•••		
Frequency:						
	mg IV every 2 wee	eks for 2 doses, then r	epeat	weeks OR	months x 1 YEAR	
☐ Every 6 r	months x 1 YEAR	,				
•						
	. ,					
PRE-MEDIC	ATIONS:					
	Acetaminophen 65	0mg PO				
	☑ Diphenhydramine 2	25mg PO or IV or Zyrt	ec 10 mg PO			
	☑ Hydrocortisone 100	= -	_	mg IV		
	 ☐ Additional Pre-Med	•		_		
MAY ADMII	NISTER IF NEEDED FOR	R ALLERGIC REACTION	l:			
✓ Nev	ada Infusion Hyperser	sitivity Reaction Ord	er Set			
☐ Oth	er:					
ACCESS: Peri	pheral IV, Port, Midline,	or PICC line				
	LO mls NS pre/post infusi		port – 100 uni	ts/ml		
	er Nevada Infusion	,	•	,		
LABS ORDER	S:	Fax results to:				
PROVIDER I	NFORMATION:					
	ame:			NPI:		
				Date:		
Point of Cor	ntact:	Phon	e:	 Email:		

Please Fax This Form With - DEMOGRAPHICS, LABS, MEDICATION LIST and H&P: 775-470-8478

^{**}Insurance verification/authorization is always obtained by Nevada Infusion prior to scheduling patients. **





PH: 775-453-0667 | Fax: 775-470-8478

Patient Name:	DOB:
Please Include Required Documentation for Expedited Order Processing & Insurance	Approval:
☐ Signed provider orders (page 1)	
\square Patient demographic and insurance information	
☐ Patient's current medication list	
\square Supporting recent clinical notes and H&P (to support primary diagnosis)	
\square Supporting clinical notes to include any past tried and/or failed therapies, intolerance	ce, benefits, or
contraindications to conventional therapy:	
\square Has the patient had a documented contraindication/intolerance or failed trial	al of a glucocorticoids?
☐ Yes OR ☐ No	
\square Does the patient have an intolerance or failed trial to a rituximab biosimilar?	
☐ Yes OR ☐ No	
If yes, which drug(s)?	_
\Box If appliable: Has the patient had a documented contraindication/intolerance	or failed trial of a DMARD.
NSAID, or conventional therapy (i.e., MTX, leflunomide)?	,
☐ Yes OR ☐ No	
If yes, which drug(s)?	<u> </u>
☐ <u>If applicable</u> : Does the patient have a contraindication/intolerance or failed the Humira, Enbrel, Stelara, Cimzia)? ☐ Yes OR ☐ No	trial to at least one biologic (i.e.,
If yes, which drug(s)?	_
☐ <u>If applicable</u> - Last known biological therapy: and last date receive	
If patient is switching to biologic therapies, please perform a wash-out period of	weeks prior to starting
rituximab.	
☐ Other medical necessity:	
Additional REQUIRED Information:	
☐ Include labs and/or test results to support diagnosis - please attach results	
☐ CBC w/platelet	
☐ Hepatitis B screening test completed. This includes Hepatitis B antigen and Hepatitis	s B core antibody total (not
IgM) - please attach results	
☐ Positive OR ☐ Negative	

Please Fax This Form With - DEMOGRAPHICS, LABS, MEDICATION LIST and H&P: 775-470-8478

**Insurance verification/authorization is always obtained by Nevada Infusion prior to scheduling patients. **

Revised: 04/2025